AZN.UK

11,384

+2.8%↑

GSK

1,453.5

+2.72%↑

HLN.UK

392.6

+1.66%↑

INDV

742

+1.92%↑

AZN.UK

11,384

+2.8%↑

GSK

1,453.5

+2.72%↑

HLN.UK

392.6

+1.66%↑

INDV

742

+1.92%↑

AZN.UK

11,384

+2.8%↑

GSK

1,453.5

+2.72%↑

HLN.UK

392.6

+1.66%↑

INDV

742

+1.92%↑

AZN.UK

11,384

+2.8%↑

GSK

1,453.5

+2.72%↑

HLN.UK

392.6

+1.66%↑

INDV

742

+1.92%↑

AZN.UK

11,384

+2.8%↑

GSK

1,453.5

+2.72%↑

HLN.UK

392.6

+1.66%↑

INDV

742

+1.92%↑

Search

Hikma Pharmaceuticals PLC

Отворен

СекторЗдравеопазване

1,955 2.3

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

1884

Максимум

1965

Ключови измерители

By Trading Economics

Приходи

226M

Продажби

1.6B

P/E

Средно за сектора

29.53

63.778

EPS

1.27

Дивидентна доходност

3.11

Марж на печалбата

14.404

Служители

9,500

EBITDA

499M

Препоръки

By TipRanks

Препоръки

Купи

12-месечна прогноза

+25.3% upside

Дивиденти

By Dow Jones

Дивидентна доходност

Средно за сектора

3.11%

2.39%

Пазарни показатели

By TradingEconomics

Пазарна капитализация

-717M

4.4B

Предишно отваряне

1952.7

Предишно затваряне

1955

Настроения в новините

By Acuity

73%

27%

358 / 386 Класиране в Healthcare

Hikma Pharmaceuticals PLC Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

2.04.2025 г., 23:55 ч. UTC

Горещи акции

Stocks to Watch: RH, Nike, Dollar Tree, Apple

2.04.2025 г., 22:50 ч. UTC

Значими двигатели на пазара

E.l.f. Beauty, Estee Lauder, Coty Shares Fall on Reciprocal Tariffs Hit

2.04.2025 г., 21:08 ч. UTC

Печалби

RH 4Q Revenue Misses Guidance, Looks to Offset Reciprocal Tariffs -- Update

2.04.2025 г., 21:00 ч. UTC

Печалби

RH 4Q Revenue Misses Guidance, Looks to Offset Reciprocal Tariffs

2.04.2025 г., 23:56 ч. UTC

Пазарно говорене

Gold Rises as Trump's Tariffs Enhance Safe-Haven Appeal -- Market Talk

2.04.2025 г., 23:44 ч. UTC

Пазарно говорене

Global Equities Roundup: Market Talk

2.04.2025 г., 23:44 ч. UTC

Пазарно говорене

Nikkei Likely to Fall After U.S. Tariff Plan -- Market Talk

2.04.2025 г., 23:44 ч. UTC

Топ новини

Some GOP Senators Break With Trump to Reject Canada Tariffs -- WSJ

2.04.2025 г., 23:32 ч. UTC

Пазарно говорене

Market Talk Roundup: Latest on U.S. Politics

2.04.2025 г., 23:32 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

2.04.2025 г., 23:32 ч. UTC

Пазарно говорене

Trump's Tariffs on Australia Conspicuously Unfriendly -- Market Talk

2.04.2025 г., 23:12 ч. UTC

Пазарно говорене

Global Equities Roundup: Market Talk

2.04.2025 г., 23:12 ч. UTC

Пазарно говорене

Trump Tariff 'Blow Bigger Than We Expected,' Capital Economics Says -- Market Talk

2.04.2025 г., 23:10 ч. UTC

Пазарно говорене

Canada, Mexico Get Short-Term Advantage From Trump's Tariff Moves -- Market Talk

2.04.2025 г., 23:09 ч. UTC

Пазарно говорене

U.S. Effective Tariff Rate Highest in 131 Years -- Market Talk

2.04.2025 г., 23:09 ч. UTC

Пазарно говорене

Market Talk Roundup: Latest on U.S. Politics

2.04.2025 г., 22:57 ч. UTC

Пазарно говорене

Australia Spared Worst Of US Tariff Hikes -- Market Talk

2.04.2025 г., 22:56 ч. UTC

Пазарно говорене

Market Talk Roundup: Latest on U.S. Politics

2.04.2025 г., 22:56 ч. UTC

Пазарно говорене

US Equity Futures Down as Tariff Hikes Stoke Recession Fears -- Market Talk

2.04.2025 г., 22:43 ч. UTC

Топ новини
Придобивния, сливания и поглъщания

AppLovin, Amazon Emerge as TikTok Bidders Ahead of Trump's Deadline, Sources Say -- 2nd Update

2.04.2025 г., 22:12 ч. UTC

Пазарно говорене

Trump's Tariff Order May Set Path for New U.S.-Canada Pact -- Market Talk

2.04.2025 г., 21:48 ч. UTC

Топ новини

The Stock Market Pain Is Just Getting Started. 'This is How You Sabotage the World's Economic Engine.' -- Barrons.com

2.04.2025 г., 21:41 ч. UTC

Пазарно говорене

USD Reaction To Trump's Tariffs Limited So far -- Market Talk

2.04.2025 г., 21:17 ч. UTC

Пазарно говорене

Market Talk Roundup: Latest on U.S. Politics

2.04.2025 г., 21:17 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

2.04.2025 г., 21:17 ч. UTC

Пазарно говорене

Mexican Peso Gains as Worst Tariff Fears Avoided -- Market Talk

2.04.2025 г., 21:04 ч. UTC

Топ новини

Trump's Tariffs Could Blow Up Big Pharma's Tax Shelter -- Heard on the Street -- Update

2.04.2025 г., 21:03 ч. UTC

Пазарно говорене

Treasury Yields, Dollar, Stock Futures Fall as Markets Digest Tariffs -- Market Talk

2.04.2025 г., 20:53 ч. UTC

Печалби

Kaiser Aluminum Changes Method From Last-In, First-Out to Weighted Avg Cost Effective Jan. 1, 2025

2.04.2025 г., 20:52 ч. UTC

Печалби

Kaiser Aluminum Changes Inventory Acctg Methodology

Сравнение с други в отрасъла

Ценова промяна

Hikma Pharmaceuticals PLC Прогноза

Ценова цел

By TipRanks

25.3% нагоре

12-месечна прогноза

Среден 2,427 GBX  25.3%

Висок 2,650 GBX

Нисък 2,000 GBX

Според 6 анализатори от Wall Street, предложили 12-месечна ценова цел за Hikma Pharmaceuticals PLC през последните три месеца.

Консенсусна оценка

By TipRanks

Купи

6 ratings

4

Купи

2

Задържане

0

Продай

Настроение

By Acuity

358 / 386 Класиране в Здравеопазване

Настроения в новините

Мечи доказателства

Волатилност

Под средното

Обем новини (RCV)

Под средното

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно Hikma Pharmaceuticals PLC

Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment provides generic injectable products primarily for use in hospitals. The Generics segment offers oral and other non-injectable generic products for the retail market. The Branded segment offers branded generics and in-licensed products to retail and hospital markets. The company provides its products in various therapeutic areas, including respiratory, oncology, and pain management. It also offers its products in solid, semi-solid, liquid, and injectable final dosage forms. The company operates in the United Kingdom, rest of Europe, North America, the Middle East, North Africa, and internationally. Hikma Pharmaceuticals PLC was founded in 1978 and is headquartered in London, the United Kingdom.